The settlement resolves allegations that Wyeth unlawfully promoted Rapamune, an immunosuppressive drug currently approved by the FDA to counteract organ rejection after kidney transplant surgery. The judgment, filed , alleges that Wyeth violated state consumer protection laws by misrepresenting the uses and benefits of Rapamune, including making representations related to: (1) the unapproved use of Rapamune following an organ transplant other than a kidney transplant; (2) the unapproved protocol of converting patients to Rapamune after initially receiving a different immunosuppressive drug and (3) using Rapamune in unapproved drug combinations.
“I will continue to protect Kentuckians from drug companies that put profits over patients,” said Attorney General Jack Conway. “Marketing of pharmaceuticals that have not been approved based on sound evidence for a particular use can be a dangerous and even deadly practice.”
The consent judgment requires Pfizer to ensure that its marketing and promotional practices do not unlawfully promote Rapamune or any Pfizer product. Specifically, Pfizer shall not:
Kentucky participated in this settlement with 42 other states including Oregon, Texas, California, Florida, Illinois, Maryland, New York, North Carolina, Pennsylvania, Alabama, Arizona, Arkansas, Colorado, Delaware, District of Columbia, Georgia, Hawaii, Indiana, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, Ohio, Oklahoma, South Dakota, Tennessee, Utah, Virginia, Washington and Wisconsin.You can follow Attorney General Conway on Twitter @kyoag,or visit the Attorney General’s Facebook page.
Information provided by Allison Martin
© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.
|< Prev||Next >|